Neurocrine Biosciences
NBIX
NBIX
527 hedge funds and large institutions have $10.7B invested in Neurocrine Biosciences in 2022 Q4 according to their latest regulatory filings, with 108 funds opening new positions, 194 increasing their positions, 169 reducing their positions, and 39 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
7% more capital invested
Capital invested by funds: $10B → $10.7B (+$692M)
6.04% less ownership
Funds ownership: 99.64% → 93.6% (-6%)
25% less funds holding in top 10
Funds holding in top 10: 12 → 9 (-3)
Holders
527
Holding in Top 10
9
Calls
$38M
Puts
$3.89M
Top Buyers
| 1 | +$181M | |
| 2 | +$69.3M | |
| 3 | +$62.3M | |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$53M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$52.1M |
Top Sellers
| 1 | -$888M | |
| 2 | -$107M | |
| 3 | -$50.6M | |
| 4 |
Franklin Resources
San Mateo,
California
|
-$42.8M |
| 5 |
ITP
Iron Triangle Partners
Cos Cob,
Connecticut
|
-$30.5M |